We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Astellas Halts Gene Therapy Trial Following Serious Adverse Event
Astellas Halts Gene Therapy Trial Following Serious Adverse Event
Astellas Pharma has stopped enrolling and dosing in a phase 1/2 clinical trial of its genetic therapy AT132 for X-linked myotubular myopathy, a rare neuromuscular disease, after a subject suffered a serious adverse event.